<DOC>
	<DOC>NCT00971607</DOC>
	<brief_summary>Ischemic postconditioning can reduce myocardial injury following myocardial infarction. A potential pharmacological agent is the anesthetic Sevoflurane. The investigators' hypothesis is that sevoflurane during primary percutaneous coronary intervention (PCI) will reduce infarct size.</brief_summary>
	<brief_title>Sevoflurane In Acute Myocardial Infarction</brief_title>
	<detailed_description>Patients with first STEMI that will be treated by primary PCI, will be randomized to sedation with Sevoflurane during the procedure or to usual care.</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Sevoflurane</mesh_term>
	<criteria>First STEMI, presenting within 6 hours after the onset of chest pain Symptoms lasting &gt; 30 minutes Persistent STsegment elevation &gt; 0.1 mV in 2 or more contiguous leads Hypersensitivity to sevoflurane or other halogenated agents Malignant hyperthermia Cardiac arrest Cardiogenic shock Previous myocardial infarction or coronary bypass surgery Preinfarction angina Heart failure (NYHA III/IV) Chronic inflammatory disease Severe renal impairment Hepatic dysfunction Use of Glyburide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Acute myocardial infarction</keyword>
	<keyword>Postconditioning</keyword>
	<keyword>Sevoflurane</keyword>
</DOC>